Kun Run Biotechnolgy (PINK:KURU)

Friday, November 19, 2010 | Web News
Revenues for the three months ended September 30, 2010 were $2.50 million, representing a decrease of $1.55 million, or 38%...
Monday, November 15, 2010 | Web News
In July 2010, Kun Run Biotechnology, Inc. received a notice from the Hainan Food and Drug Administration that the agency would investigate certain products of the Company...
Monday, September 13, 2010 | Web News
On September 3, 2010, Kun Run Biotechnology, Inc. (the “Company”) entered into a Redemption Agreement by and between...
See All Research...

Kun Run Biotech came public via a reverse merger on September 16, 2008

Kun Run Biotechnology, Inc., together with its subsidiaries, engages in manufacture and sale of polypeptide medicines. It uses solid phase peptide synthesis (SPPS) and advanced purifying technology to produce various therapeutic polypeptide drugs, of which is 'TP-5' most known for efficiently regulating humans' immune systems in order to defend and cure malignant diseases. The company maintains two state-of-art manufacturing plants and possesses one of the largest peptide synthesizing capacities across Asia.

Web site: http://www.zhonghe.cn

Last updated April 1, 2009